Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAAFT-3: RF Ablation vs Antiarrhythmic Drugs for Persistent AF
NCT04037397Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Sep 2019
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Recurrence of symptomatic Atrial Fibrillation at 18 months. Started Sep 2019; status: completed.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04037397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037397.